Shares of Atara Biotherapeutics, Inc. (ATRA), are trading 3 percent higher in pre-market on Tuesday after the company engaged in T-cell immunotherapy, announced efficacy and safety results from its study investigating tabelecleucel (tab-cel) for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease.
from RTT - Before the Bell https://ift.tt/3IHb7Zc
via IFTTT
No comments:
Post a Comment